Eucrates Biomedical Acquisition Corp. – NASDAQ:EUCR

Financial Health
0
1
2
3
4
5
6
7
8
9

Eucrates Biomedical Acquisition Corp. stock price monthly change

-1.08%
month

Eucrates Biomedical Acquisition Corp. stock price quarterly change

+0.20%
quarter

Eucrates Biomedical Acquisition Corp. stock price yearly change

+1.41%
year

Eucrates Biomedical Acquisition Corp. key metrics

Market Cap
 42.22M
Enterprise value
 N/A
P/E
 53.42
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 -28.48
PEG ratio
 N/A
EPS
 0.54
Revenue
 N/A
EBITDA
 -2.57M
Income
 5.44M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Eucrates Biomedical Acquisition Corp. stock price history

Eucrates Biomedical Acquisition Corp. stock forecast

Eucrates Biomedical Acquisition Corp. financial statements

Profit Margin

Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR): Profit margin
Mar 2022 0 2.78M
Jun 2022 0 905.24K
Sep 2022 0 1.20M
Dec 2022 0 546.7K
EUCR income statement history

Debt to Assets

Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR): Debt to assets
Mar 2022 105182110 4.55M 4.33%
Jun 2022 105176937 4.11M 3.91%
Sep 2022 105516334 3.93M 3.73%
Dec 2022 12485358 3.94M 31.64%
EUCR balance sheet history

Cash Flow

Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR): Cash Flow
Mar 2022 -140.08K 0 250K
Jun 2022 -54.30K 0 0
Sep 2022 -44.72K 0 0
Dec 2022 -391.17K 0 -92.84M
EUCR cash flow history

Eucrates Biomedical Acquisition Corp. other data

Eucrates Biomedical Acquisition Corp.
Hedge Funds Holdings Q1 2023

0.02% -7.06%
of EUCR is owned by hedge funds
1 -5
hedge funds hold EUCR stock
647 -297.41K
shares is hold by hedge funds
EUCR hedge funds holdings changes

Frequently Asked Questions (FAQ)

  • When is Eucrates Biomedical Acquisition Corp.'s next earnings date?

    Unfortunately, Eucrates Biomedical Acquisition Corp.'s (EUCR) next earnings date is currently unknown.

  • Does Eucrates Biomedical Acquisition Corp. pay dividends?

    No, Eucrates Biomedical Acquisition Corp. does not pay dividends.

  • How much money does Eucrates Biomedical Acquisition Corp. make?

    Eucrates Biomedical Acquisition Corp. has a market capitalization of 42.22M.

  • What is Eucrates Biomedical Acquisition Corp.'s stock symbol?

    Eucrates Biomedical Acquisition Corp. is traded on the NASDAQ under the ticker symbol "EUCR".

  • What is Eucrates Biomedical Acquisition Corp.'s primary industry?

    Company operates in the Financial Services sector and Shell Companies industry.

  • How do i buy shares of Eucrates Biomedical Acquisition Corp.?

    Shares of Eucrates Biomedical Acquisition Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • When Eucrates Biomedical Acquisition Corp. went public?

    Eucrates Biomedical Acquisition Corp. is publicly traded company for more then 4 years since IPO on 28 Dec 2020.

  • Where are Eucrates Biomedical Acquisition Corp.'s headquarters?

    Eucrates Biomedical Acquisition Corp. is headquartered at 250 West 55th Street, New York, NY.

  • How can i contact Eucrates Biomedical Acquisition Corp.?

    Eucrates Biomedical Acquisition Corp.'s mailing address is 250 West 55th Street, New York, NY and company can be reached via phone at +212 7105220.

Eucrates Biomedical Acquisition Corp. company profile:

Eucrates Biomedical Acquisition Corp.

Exchange:

NASDAQ

Full time employees:

0

Industry:

Shell Companies

Sector:

Financial Services

Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York.

+212 7105220
250 West 55th Street
New York, NY 10019

CIK: 0001822929
ISIN: VGG3141W1068
CUSIP: G3141W106